Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma

NCT06615479 is registered in ClinicalTrials.gov with Juno Therapeutics, Inc., a Bristol-Myers Squibb Company as lead sponsor.

NCT NCT06615479
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06615479 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase
Phase 3
Overall status
Recruiting
Start date
March 12, 2025
Completion date
June 22, 2032
Enrollment
440 (estimated)
Sites
141

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory multiple myeloma (rrmm)